A Platform for Boosting Efficiency of Therapeutic RNA Editing

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Single-point mutations can give rise to a wide spectrum of genetic diseases. Recent therapeutic approaches aim at editing the mutated mRNA, providing a safe, reversible and tunable treatment. However, these methods are currently not efficient due to knowledge gaps in the understanding of the rules determining RNA editing. Here we provide a powerful method to enhance the efficiency of RNA editing for treating genetic diseases associated with single-point mutations.


Background and Unmet Need

Single-point nonsense or missense mutations are responsible for several diseases, including neurofibromatosis, sickle-cell anemia, cystic fibrosis etc. Since therapeutic genome editing may give rise to severe side-effects, targeted RNA editing has become a major interest in recent years, offering a potentially safer alternative to correct single-point mutations. One of the most prevalent forms of RNA editing is Adenosine (A) to Inosine (I) RNA editing, in which adenosines are deaminated into inosines by adenosine deaminase acting on RNA (ADAR) enzymes.

Inosine is read as guanine by the translational machinery of the cell, instead of the original adenosine that was encoded in the genome. Using different strategies, several groups have sought to guide either the endogenous or engineered exogenous editing machinery towards pre-designed targets. One such strategy is by delivering antisense guide RNA oligos that create editable structures around a target adenosine that will be recognized by ADAR. However, all these endeavors resulted in low editing efficiency, since the fundamental rules determining which sites within the RNA will be edited and to what extent remain poorly understood.

The Solution

The group of Prof. Schraga Schwartz conducted a large-scale systematic screening to uncover the rules that govern A-to-I RNA editing. The rules they discovered enable increased targeting efficiency.

Technology Essence

The group conducted a large-scale systematic screening to explore the structure and sequence context determining editability. They have generated two highly edited hairpin shaped RNA reporters, and designed an oligo library with systematically disrupted sequences and structures. These constructs were then transfected into several human and mouse cell lines. Single-molecule level editing transcriptome analysis of the of the transfected cell lines revealed a set of structural principles independent of sequence that can significantly improve A-to-I editing efficiency. For instance, they show that editing is robustly induced at fixed intervals from structural disruption. The group went on to show that an RNA targeting oligo designed based on these rules increased editing by 3-fold.

Applications and Advantages

  • Safe, reversible and tunable relative to genome editing approaches
  • A more effective RNA editing method compared to other available RNA editing platforms.

Development Status

The team uncovered the rules for efficient site-directed RNA editing and demonstrated their applicability by designing a targeting mRNA for SMAD4 to recruit endogenous ADAR1.


Uzonyi, Anna, Ronit Nir, Ofir Shliefer, Noam Stern-Ginossar, Yaron Antebi, Yonatan Stelzer, Erez Y. Levanon, and Schraga Schwartz. 2021. “Deciphering the Principles of the RNA Editing Code via Large-Scale Systematic Probing.” Molecular Cell, April. https://doi.org/10.1016/j.molcel.2021.03.024 [1]

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Medical Research
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support